Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sagimet Biosciences, Inc. Class A ( (SGMT) ) just unveiled an update.
Sagimet Biosciences Inc. announced its entrance into a license agreement with TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries Ltd., on December 17, 2025. This collaboration grants Sagimet a global, exclusive license to TAPI’s innovative resmetirom active pharmaceutical ingredient (API), supporting the development of a fixed-dose combination (FDC) product featuring denifanstat and resmetirom. The program aims to address critical unmet needs for cirrhosis patients affected by F4-stage MASH. This move marks a significant step forward for Sagimet’s research and development efforts as it aligns with preclinical data showing synergy in treating liver diseases, positioning Sagimet for further advancement in the field.
The most recent analyst rating on (SGMT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.
Spark’s Take on SGMT Stock
According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.
Sagimet Biosciences’ overall score reflects substantial financial difficulties marked by persistent losses and reliance on external funding. While technical indicators show short-term bullish momentum, the lack of profitability and negative equity pose significant long-term risks. Valuation metrics further highlight the challenges in viewing this stock as an attractive investment.
To see Spark’s full report on SGMT stock, click here.
More about Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways. The company is focused on creating therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other related conditions using innovative solutions such as fatty acid synthase (FASN) inhibitors and resmetirom combinations.
Average Trading Volume: 564,627
Technical Sentiment Signal: Hold
Current Market Cap: $187.6M
For a thorough assessment of SGMT stock, go to TipRanks’ Stock Analysis page.